Prenetics Global以4600万美元剥离ACT Genomics

2025-06-18 20:01

Prenetics Global (NASDAQ:PRE) announced the divestment of its majority stake in ACT Genomics to Delta Electronics in a deal valued at up to $71.78Mn.
Prenetics will receive ~$46M in cash, boosting its pro-forma cash reserves to $86M and short-term assets to $117Mn, with zero debt.
The move completes Prenetics' strategic transformation, simplifying its business and focusing on high-margin consumer health.
Prenetics Q1 2025 revenue reached $14.4M, a 336.5% year-over-year increase; full-year revenue guidance raised to $80M – $100M (excluding ACT Genomics).
Post-divestment, Prenetics focuses on three core brands: IM8, CircleDNA, and Europa.
Prenetics is exploring innovation in treasury strategies, including digital assets and Bitcoin adoption.
PRE shares up 1.2% premarket on Wednesday.
Source: Press release

More on Prenetics Global